News

Johnson & Johnson Innovation Grant Aimed at Veteran Healthcare

A 2021 report by the U.S. Department of Health and Human Services found that Veterans are significantly more likely to develop multiple chronic health conditions in their lifetime like hypertension, arthritis, and cancer compared to non-Veterans. [1] To help treat wounded warriors and keep the military community healthy, we feel we must seek to identify and advance solutions with the potential to help address their medical needs.

To that end, Johnson & Johnson Innovation, together with Johnson & Johnson Office of Military and Veterans Affairs, is proud to continue the Veterans Lead QuickFire Challenge series. Innovators are invited to submit potentially ground-breaking ideas that aim to directly address the health care needs of the military community including cardiovascular disease [2], kidney disease [3], oncology [4], orthopedic and musculoskeletal disease [5], physical trauma management [6], respiratory health [7], and vision loss. [8]

The innovator(s) with the best idea, technology, or potential solution can receive grant funding from up to a total of $250,000, access to the Johnson & Johnson Innovation – JLABS ecosystem, and mentorship from experts across the Johnson & Johnson Family of Companies*.

* Subject to the execution of the necessary documentation and award agreement

 

Application Process

Potential solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:

  • Uniqueness of the idea
  • Potential impact on human health, specifically the military-connected community’s health
  • Feasibility of the idea
  • Thoroughness of approach
  • Identification of key resources and plan to further idea

The challenge is now accepting applications. The deadline to apply is September, 17 2021.

Recent News

09/17/2026

Rivanna Announces New CMS Procedure Code for Computer-aided Neuraxial Guidance

RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the Centers for Medicare & Medicaid Services (CMS) has established ICD-10-PCS code XEZU3HC, effective for inpatient discharges beginning October 1, 2026. The code identifies computer-aided intraprocedural navigation in the spinal canal using ultrasound imaging with continuous needle tracking via a percutaneous approach during neuraxial anesthesia.

09/17/2026

From Lab to Three Continents: Agrospheres and FMC Corporation Advance Bioinsecticide Pipeline into Global Field Trials

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and FMC Corporation (NYSE: FMC), a global leader in agricultural sciences, today announced a significant advancement in its ongoing collaboration. Two proprietary RNA-based biomolecule candidates from AgroSpheres’ pipeline are now entering global field trial development, marking the transition from discovery into real-world testing across three

09/15/2026

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. (“Actio”) for $820 million upfront. Actio is now a wholly-owned subsidiary of Jazz. “ABS-1230 holds the promise of being a transformative, first-in-class therapy for individuals living with KCNT1-related epilepsy,” said Renee Gala, president and